Detalles de la búsqueda
1.
Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1-mutated and PTEN-wild-type triple-negative breast cancer cells.
Mol Carcinog
; 56(5): 1383-1394, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27864890
2.
Cholinergic Neurotransmission in the Posterior Insular Cortex Is Altered in Preclinical Models of Neuropathic Pain: Key Role of Muscarinic M2 Receptors in Donepezil-Induced Antinociception.
J Neurosci
; 35(50): 16418-30, 2015 Dec 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-26674867
3.
Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells.
Sci Rep
; 10(1): 6367, 2020 04 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-32286420
4.
Homoharringtonine, an approved anti-leukemia drug, suppresses triple negative breast cancer growth through a rapid reduction of anti-apoptotic protein abundance.
Am J Cancer Res
; 9(5): 1043-1060, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31218111
5.
Quantification of hypoxia-related gene expression as a potential approach for clinical outcome prediction in breast cancer.
PLoS One
; 12(4): e0175960, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28430808
6.
Acid-Sensing Ion Channel 1a in the amygdala is involved in pain and anxiety-related behaviours associated with arthritis.
Sci Rep
; 7: 43617, 2017 03 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28321113
7.
Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer.
Oncotarget
; 7(45): 73618-73637, 2016 Nov 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27655662
8.
Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer.
PLoS One
; 6(9): e25080, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21966417
Resultados
1 -
8
de 8
1
Próxima >
>>